Other paediatric projects and events

Date:
06-DEC-2018
Title:
PRES Vaccination Working Party: the study on Safety of MMR booster in children treated with biologic therapy and DMARDs / Methotrexate is initiated
Location:
Description:
Dear Friends,

We would like to share with you the communication below from Dr. Natasa Toplak and Prof. Yosef Uziel regarding the study on safety of MMR booster in children treated with biologic therapy and DMARDs / Methotrexate coordinated by the PRES Vaccination Working Party.

Here is the link where you can find the study-related files:
https://www.printo.it/docs/PRES_Vaccination_Group_study-docs.zip

Please see contacts below in the communication for any info.

Best regards,
Nicola and Alberto for PRINTO
 
***

Dear Colleagues,

The study on safety of MMR booster in children treated with biologic therapy and DMARDs / Methotrexate was initiated in PRES Vaccination Working Party because we believe that it is important to protect our patients treated with immunosuppressive therapy, against diseases that can be prevented, also by live attenuated vaccines. In the light of measles epidemics in Europe, the protection against measles is mandatory. Some doctors in rheumatology community already gave booster MMR doses to patients treated with MTX and also biologics, because the risk of vaccination is probably much lower than the risk of infection. But the evidence for this is low, non-existent. So we decided first to gather the retrospective data.
We are collecting patients that received MMR booster and possible side effects, if appeared, after vaccination. So far we collected more than 20 patients that received MMR booster while treated with biologics. No side effects were noted. But it is important that we gather as much as possible, every patient counts.
This is a retrospective data collection, not a registry, just a simple excel table. The prospective part will be based on the data about safety of MMR booster from retrospective study.
If you are aware of any patients with rheumatic disease treated with biologic therapy and / or methotrexate that received booster MMR while on therapy, please join us in our effort.
Principal investigator of a study is Sefi Uziel- please contact him or contact vaccination working party chair- Natasa Toplak.

We would like to send an abstract to EULAR congress so if possible we will need the data until the end of December.

Natasa Toplak, chair Vaccination WP
natasatoplak212@gmail.com

Sefi Uziel, PI of the study
uziely@zahav.net.il